Insider Selling: BioSyent Inc. (CVE:RX) Insider Sells 65,000 Shares of Stock

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 65,000 shares of the stock in a transaction dated Thursday, April 13th. The stock was sold at an average price of C$7.70, for a total value of C$500,500.00.

FAX Capital Corp. also recently made the following trade(s):

• On Friday, November 22nd, FAX Capital Corp. sold 230,800 shares of BioSyent stock. The shares were sold at an average price of C$11.12, for a total value of C$2,566,496.00.

BioSyent Trading Down 1.1 %

Shares of RX stock opened at C$11.38 on Friday. The firm’s 50-day simple moving average is C$11.09 and its 200-day simple moving average is C$10.32. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. BioSyent Inc. has a 1-year low of C$8.24 and a 1-year high of C$11.74. The firm has a market cap of C$131.89 million, a P/E ratio of 19.18 and a beta of 0.93.

BioSyent (CVE:RX) last issued its quarterly earnings results on Monday, August 26th. The company reported C$0.13 EPS for the quarter, hitting the consensus estimate of C$0.13. The firm had revenue of C$8.95 million during the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. As a group, equities analysts forecast that BioSyent Inc. will post 0.6944444 EPS for the current year.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.